Spectrum Pharmaceuticals to Develop Biosimilar Rituximab - - BioPharm International

ADVERTISEMENT

Spectrum Pharmaceuticals to Develop Biosimilar Rituximab


BioPharm Bulletin

California-based biopharmceutical company Spectrum Pharmaceuticals will develop a biosimilar version of Swiss pharmaceutical giant Roche Holding AG's monoclonal antibody drug rituximab. Spectrum aims to achieve this through a partnership with Viropro Inc (Irvine, CA).

Rituximab, which is sold as Rituxan by the Genentech unit of Swiss drugmaker Roche Holding, is used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis.

The financial terms of the agreement weren't disclosed. Spectrum's deal with Viropro comes after Teva Pharmaceutical Industries launched efforts last May to develop a biosimilar of rituximab. Roche's rituximab loses patent protection in 2012.

“We are excited at the opportunity to develop our own proprietary biosimilar formulation of rituximab in anticipation of patent expirations for rituximab over the coming years,” said Rajesh C. Shrotriya, MD, Chairman, Chief Executive Officer, and President of Spectrum Pharmaceuticals, Inc., in a company statement.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

NIH Launches Human Safety Study of Ebola Vaccine Candidate
August 29, 2014
Suppliers Seek to Boost Single-Use Technology
August 21, 2014
Bristol-Myers Squibb and Celgene Collaborate on Immunotherapy and Chemotherapy Combination Regimen
August 20, 2014
FDA Warns about Fraudulent Ebola Treatments
August 15, 2014
USP Awards Analytical Research
August 15, 2014
Author Guidelines
Source: BioPharm Bulletin,
Click here